Ligand Pharmaceuticals Incorporated (LGND)

69,89 +1,36 (+1,98%) Alla chiusura: 04:00PM EDT

Ligand Pharmaceuticals Incorporated

555 Heritage Drive
Suite 200
Jupiter, FL 33458
United States
858 550 7500
https://www.ligand.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 58

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Matthew E. Korenberg	President & COO	760,99k	N/D	1975
Mr. Octavio Espinoza	Chief Financial Officer	457,19k	N/D	1971
Mr. Andrew T. Reardon J.D.	Chief Legal Officer & Secretary	480,16k	N/D	1975
Mr. Scott M. Plesha	Chief Executive Officer	N/D	N/D	1965
Mr. Paul J. Hadden	Senior Vice President of Investments & Business Development	N/D	N/D	N/D
Simon Latimer	Head of Investor Relations	N/D	N/D	N/D
Mr. Todd Pettingill	Director of Corporate Development	N/D	N/D	N/D
Ms. Audrey Warfield-Graham	Chief People Officer	N/D	N/D	N/D
Dr. Keith Marschke	Senior Vice President of Biology & Scientific Affairs	N/D	N/D	N/D
Dr. Vincent D. Antle	Senior Vice President of Technical Operations & QA - Capitsol	N/D	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Governance aziendale

L'ISS Governance QualityScore di Ligand Pharmaceuticals Incorporated al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 5; diritti degli azionisti: 5; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.